1201643-71-1

Basic information

• Product Name: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide
• Synonyms: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide;N-[5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methansulfonamide;5-Methanesulfonylamino-pyridine-3-boronic acid pinacol ester;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (5-(methylsulfonamido)pyridin-3-yl)boronate;N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]- Methanesulfonamide
• CAS NO: 1201643-71-1
• Molecular Formula: C₁₂H₁₉BN₂O₄S
• Molecular Weight: 298.16626
• Mol File: 1201643-71-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide(1201643-71-1)
• EPA Substance Registry System: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide(1201643-71-1)

Safety Data

• Hazardous Substances Data: 1201643-71-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide is used as a building block for the synthesis of various organic molecules due to its unique structure and reactivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, this compound is employed as a key intermediate in the development of pharmaceuticals, contributing to the creation of new drugs with potential therapeutic applications.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
The boron-containing group in N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide allows it to participate in Suzuki-Miyaura cross-coupling reactions, which are extensively used in the synthesis of biaryl compounds. This application is crucial for the production of complex organic molecules with potential applications in various industries, including pharmaceuticals and materials science.
Used in Pharmaceutical Development:
N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide is used as a precursor in the synthesis of pharmaceuticals, enabling the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Synthesis:
In the agrochemical industry, this compound is utilized as a building block for the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals to enhance crop protection and yield.

Upstream product

• 1083326-18-4 N-(5-bromopyridin-3-yl)methanesulfonamide 
• 73183-34-3 bis(pinacol)diborane 
• 13535-01-8 3-amino-5-bromopyridine 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF

Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.